BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22421007)

  • 1. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
    Kostakoglu L; Schöder H; Johnson JL; Hall NC; Schwartz LH; Straus DJ; LaCasce AS; Jung SH; Bartlett NL; Canellos GP; Cheson BD;
    Leuk Lymphoma; 2012 Nov; 53(11):2143-50. PubMed ID: 22421007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
    Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
    Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
    Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
    J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
    Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
    J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
    Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
    Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
    Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
    Mylam KJ; Kostakoglu L; Hutchings M; Coleman M; Lamonica D; Czuczman MS; Diehl LF; Nielsen AL; Jensen P; Loft A; Hendel HW; Iyer V; Leppä S; Jyrkkiö S; Holte H; Eriksson M; Gillstrøm D; Hansen PB; Seppänen M; Hjorthaug K; Brown Pde N; Pedersen LM
    Leuk Lymphoma; 2015 Jul; 56(7):2005-12. PubMed ID: 25330442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
    Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
    Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.
    Le Roux PY; Gastinne T; Le Gouill S; Nowak E; Bodet-Milin C; Querellou S; Mahe B; Dubruille V; Blin N; Salaun PY; Bodere-Kraeber F
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1064-71. PubMed ID: 21308370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
    Sickinger MT; von Tresckow B; Kobe C; Engert A; Borchmann P; Skoetz N
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010533. PubMed ID: 25572491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined prognostic role of TARC and interim
    Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
    Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
    Fuchs M; Goergen H; Kobe C; Kuhnert G; Lohri A; Greil R; Sasse S; Topp MS; Schäfer E; Hertenstein B; Soekler M; Vogelhuber M; Zijlstra JM; Keller UB; Krause SW; Wilhelm M; Maschmeyer G; Thiemer J; Dührsen U; Meissner J; Viardot A; Eich H; Baues C; Diehl V; Rosenwald A; von Tresckow B; Dietlein M; Borchmann P; Engert A
    J Clin Oncol; 2019 Nov; 37(31):2835-2845. PubMed ID: 31498753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome.
    Han EJ; O JH; Yoon H; Jung SE; Park G; Choi BO; Cho SG
    Medicine (Baltimore); 2016 Sep; 95(39):e4983. PubMed ID: 27684851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma.
    Jiang C; Su M; Kosik RO; Zou L; Jiang M; Tian R
    Clin Nucl Med; 2015 Oct; 40(10):767-73. PubMed ID: 26164182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
    Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.